Skip to content
DataLookout
Menu

Roche / Genentech clinical trial pipeline

Get alerts when Roche / Genentech's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

85 trials changed in the last 30 days: 2 stopped, 24 with notable changes, 59 with minor changes only.

  1. Minor: CEVOLUTION · Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care · Previously Treated Multiple Myeloma Primary completion pushed from Oct 31, 2028 to Nov 30, 2028 Hoffmann-La RochePhase 3 NCT07555938
  2. Minor: MorningSun · Mosunetuzumab Monotherapy · Select B-Cell Malignancies Primary completion pushed from Jul 31, 2027 to Oct 1, 2027 Genentech, Inc.Phase 2 NCT05207670
  3. Stopped: See How RO7763505 Works and How Safe it is When Given to Healthy People and · Stable Heart Disease Trial terminated Hoffmann-La RochePhase 1 NCT07495813
  4. Minor: STARTRK-2 · Basket Study of Entrectinib (RXDX-101) · Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Trial completed Hoffmann-La RochePhase 2 NCT02568267
  5. Minor: dRAvite-LTE · Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations Hoffmann-La RochePhase 2 NCT07620392
  6. Notable: RO7821657 · Solid Tumors Recruitment opened Hoffmann-La RochePhase 1 NCT07883577
  7. Minor: WILL-EMI · Emicizumab · Type 3 Von Willebrand Disease Primary completion pushed from Apr 30, 2027 to Oct 6, 2027 Hoffmann-La RochePhase 3 NCT06998524
  8. Minor: SOLUNA · Mosunetuzumab · Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Primary completion pushed from Feb 28, 2028 to Aug 11, 2028 Hoffmann-La RochePhase 2 NCT07598396
  9. Minor: ZUPREME-5 · Petrelintide · Overweight or Obesity and Established Cardiovascular Disease Trial sites expanded: 3 → 11 locations Hoffmann-La RochePhase 3 NCT07843472
  10. Notable: ZEBRHA 3 · NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children Recruitment opened Hoffmann-La RochePhase 3 NCT07838194
  11. Notable: Inavolisib and Fulvestrant With or Without Palbociclib · Advanced Breast Cancer (ABC) and Type 2 Diabetes Start date pushed from Oct 30, 2026 to Nov 30, 2026 Hoffmann-La RochePhase 2 NCT07748208
  12. Minor: Astegolimab · Chronic Obstructive Pulmonary Disease (COPD) Enrollment closed, study ongoing Hoffmann-La RochePhase 3 NCT05878769
  13. Minor: INAVO122 · Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo · PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer Primary completion pushed from Dec 31, 2026 to May 3, 2027 Hoffmann-La RochePhase 3 NCT05894239
  14. Notable: ALLEGORY · Obinutuzumab · Systemic Lupus Erythematosus Results posted: Nov 12, 2026 Hoffmann-La RochePhase 3 NCT04963296
  15. Notable: Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide · Type 2 Diabetes Enrollment reopened Hoffmann-La RochePhase 2 NCT07112872
  16. Minor: Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant · ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Trial sites expanded: 8 → 13 locations Genentech, Inc.Phase 3 NCT07541079
  17. Minor: Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib · Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Study completion pushed from Jul 31, 2027 to Jul 28, 2028 Hoffmann-La RochePhase 3 NCT04546009
  18. Minor: Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 · B-Cell Non-Hodgkin Lymphoma Primary and study completion moved earlier from Aug 5, 2029 to Apr 30, 2029 Hoffmann-La RochePhase 1 NCT05169515
  19. Notable: Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Primary completion pushed from Jan 31, 2027 to Jul 31, 2029 Hoffmann-La RochePhase 2 NCT06806033
  20. Notable: GDC-7035 With Anti-Cancer Therapies · KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma Start date pushed from Oct 31, 2026 to Nov 30, 2026 Genentech, Inc.Phase 1 NCT07859085
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07937852 A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants… Phase 3 Not Yet Recruiting
2026-11-05 NCT07918846 A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity… Phase 3 Not Yet Recruiting
2026-10-30 NCT07905924 A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or… Phase 1 Not Yet Recruiting
2026-10-22 NCT07889648 A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in… Phase 3 Not Yet Recruiting

Active trials by phase

Phase 1
54
Phase 1/2
23
Phase 2
50
Phase 2/3
3
Phase 3
91
Phase 4
9
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 47

Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free